By Dr. San Kiang, J-Star Research / Porton The business goal of most CMC development is to reach FIH as fast as possible. However, before IND or Phase 1,...
By Dr. Simon Bates, Rigaku Americas Corp X-ray powder diffraction has been the gold standard for solid state pharmaceutical analysis for quite some time. However, when it comes to...
By Dr. Bob Docherty, Pfizer The focus would be on solid form screen & selection, crystallization process development, pre-formulation evaluations, particle engineering and projecting the API attributes to drug...
By Dr. Ahmad Sheikh, AbbVie While new chemical entities represent majority of the drugs approved in the last five years, the diversity and complexity of these molecules continue...
By Dr. Jeremy M. Merritt, Eli Lilly and Co. Abstract: pending
